Category | Partnering

When de-risking, relationships matter: How using key strategies can get you to your next innovative partnership

Posted on 10 August 2015

An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

Tags: , , , ,

Sorrento Sells Cynviloq for $1.3B to NantPharma

Posted on 15 May 2015

Sorrento Therapeutics agreed to sell its drug candidate Cynviloq (paclitaxel nanoparticle polymeric micelle) for up to $1.3 billion to NantPharma.

Tags: ,

Agilis Biotherapeutics enters license agreement with the University of South Florida

Posted on 13 May 2015

Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer’s Research Institute at the University of South Florida, more »

Tags: , ,

Pfizer in asset purchase and option to acquire AM-Pharma

Posted on 12 May 2015

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

Tags: ,

EMD Serono and Pfizer in co-promotion agreement for Xalkori

Posted on 06 May 2015

EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

Tags: ,

Pfizer in collaboration agreement for lupus study

Posted on 05 May 2015

23andMe announced the launch of the Lupus Research Study in collaboration with Pfizer.

Tags: ,

Bayer and Isis in ISIS-FXIRx licensing pact

Posted on 05 May 2015

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals on ISIS-FXIRx

Tags: , ,

Roche and 4D Molecular partner for AAV vectors

Posted on 30 April 2015

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors

Tags: , ,

AstraZeneca and Innate Pharma in IPH2201 deal

Posted on 28 April 2015

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca

Tags: , ,

Celgene and AstraZeneca in MEDI4736 pact

Posted on 28 April 2015

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies

Tags: , ,